Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 12/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25417069 | 1.00 | TRPM8 (0.41) | TRPM8LMNATP53POLBTDP1 | |
| SCHEMBL31421526 | 0.85 | TRPM8 (0.39) | TRPM8LMNATP53 | |
| SCHEMBL28667493 | 0.75 | MAPK1 (0.42) | TRPM8LMNATP53POLBTDP1 | |
| SCHEMBL23499142 | 0.74 | THRB (0.39) | TRPM8LMNATP53POLBTDP1 | |
| SCHEMBL25167989 | 0.74 | MEN1 (0.37) | TRPM8LMNAPOLBALDH1A1KMT2A | |
| SCHEMBL23498368 | 0.72 | THRB (0.39) | TRPM8LMNAPOLBTDP1KDM4E | |
| SCHEMBL25169414 | 0.70 | TRPM8 (0.38) | TRPM8LMNATP53POLBMAPT | |
| SCHEMBL30407536 | 0.69 | TSHR (0.44) | LMNAKDM4EALDH1A1MAPK1MAPT | |
| SCHEMBL25415026 | 0.69 | TSHR (0.44) | LMNAKDM4EALDH1A1MAPK1MAPT | |
| SCHEMBL25175670 | 0.68 | L3MBTL1 (0.41) | LMNATP53POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129090-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS EUROPE GMBH (CH) | 2025-04-24 | — | — | US | disclosed |
| EP-4426708-A1 | TRIAZINE AMINO DERIVATIVES FOR TREATING SCA3 | Skyhawk Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081860-A1 | TRIAZINE AMINO DERIVATIVES FOR TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129090-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | TRPM8 4137/4885LMNA 335/4885TP53 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.